Mavacamten, a First-in-Class Cardiac Myosin Inhibitor for Obstructive Hypertrophic Cardiomyopathy

CONCLUSIONS: Mavacamten is a new option for patients with refractory obstructive hypertrophic cardiomyopathy and an ejection fraction ≥55% but its pricing makes therapy not cost-effective. Final health outcomes are not fully elucidated and additional studies are needed to determine long-term effects.PMID:35950315 | DOI:10.1177/10600280221117812
Source: The Annals of Pharmacotherapy - Category: Drugs & Pharmacology Authors: Source Type: research